QIAGEN’s QuantiFERON-TB test wins tender for testing of Republic of Korea Armed Forces recruits
Jan 26 2017

QIAGEN’s QuantiFERON-TB test wins tender for testing of Republic of Korea Armed Forces recruits

Selected for screening of 340,000 recruits in 2017 as part of national TB control strategy

Hilden, Germany, and Seoul, Korea, January 26, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Gold (QFT), the modern standard for accuracy in diagnosing latent tuberculosis (TB) infection, has been selected by the Republic of Korea Armed Forces for the screening of more than 340,000 recruits during 2017.

Korea has one of the highest active TB incidence rates among industrialized countries, with more than 32,000 new cases and 2,300 deaths per year. The government has adopted a strategy to eliminate the disease, including preventive screening of at-risk groups and treatment of individuals with latent tuberculosis infection (LTBI), in line with recommendations of the World Health Organization (WHO).

Furthermore, the Korea Centers for Disease Control and Prevention (CDC) in 2016 selected QuantiFERON-TB for nationwide contact screening of people at risk of infection through close contact with active TB patients.

“We are pleased to support the efforts in Korea to take a comprehensive, best-practice approach to TB control, and are collaborating with authorities, distributors and laboratories to implement a program for latent TB screening using QuantiFERON-TB as the modern test of choice,” said Dr. Masae Kawamura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN. QuantiFERON-TB is the standard test used by national laboratories in Korea and won this competitive tender for the Republic of Korea Armed Forces based on its proven workflow and cost effectiveness.”

Tuberculosis is a contagious bacterial infection spread primarily through the air. Patients with the active pulmonary form of the disease can spread it through coughing. In 2015, WHO estimates, there were 10.4 million new cases of active TB worldwide and 1.8 million deaths from TB. In latent TB infection, the bacterium infects a person but who does not develop symptoms unless it progresses to the active disease. On a global basis, approximately one-third of people are estimated to have LTBI, and about 5-10% of those individuals, if untreated, will progress to active tuberculosis at some point. Screening of high-risk individuals and treatment for LTBI play an important role in tuberculosis control efforts in a growing number of countries.

QIAGEN partners with governments and health organizations around the world to fight tuberculosis and continues to develop innovative new technologies. QuantiFERON-TB Gold is the modern standard for diagnosing latent TB infection – faster, less labor-intensive and more accurate than the century-old tuberculin skin test. QFT’s clinical reliability and simpler administration enhance the accuracy of screening and improve the cost-effectiveness of TB control. In 2015 QIAGEN launched QuantiFERON-TB Gold Plus (QFT-Plus) in Europe and other markets as a fourth-generation test with CE-IVD marking. More than 30 million tests using QuantiFERON-TB technology have been distributed globally. To learn more about QFT and QFT-Plus, please visit http://wwwQuantiFERON.com.

 

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2016, QIAGEN employed approximately 4,700 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

SOCIAL SHARING

Share this page